The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.

The present invention relates to modified Mannheimia haemolytica (M. haemolytica) lktCA gene cluster cassettes, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions. Also described herein are Mycoplasma bovis (M. bovis) protective antigens, compositions comprising such antigens, methods of using such antigens and compositions, and kits comprising such antigens and compositions. Also described herein are modified M. haemolytica lktCA gene cluster cassettes engineered to express M. bovis protective antigens, compositions comprising such cassettes, methods of using such cassettes and compositions, and kits comprising such cassettes and compositions.

Embodiments of the invention include immunogenic compositions that comprise an attenuated recombinant Francisella tularensis subspecies holarctica Live Vaccine Strain (LVS) having a deletion in a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens present on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Embodiments of the invention also include methods of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant Live Vaccine Strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens expressed by a severe acute respiratory syndrome coronavirus 2 (SAR8-CoV-2) polypeptide.

The present embodiments provide for an S. aureus (SA) Multiple Antigen Presenting System (MAPS) immunogenic composition comprising an immunogenic polysaccharide which induces an immune response, where at least one S. aureus (SA) peptide or polypeptide antigen is associated to the immunogenic polysaccharide by complementary affinity molecules. In some embodiments, the immunogenic polysaccharide can be an antigenic capsular polysaccharide of a Type 5 or Type 8 from S. aureus, or alternatively, a different immunogenic capsular or noncapsular polysaccharide, and where the protein or peptide SA antigens are indirectly linked via an affinity binding pair. The present SA-MAPS immunogenic compositions can elicit both humoral and cellular immune responses to the immunogenic polysaccharide and one or multiple SA antigens at the same time.

A Fim3-producing BPZE1 derivative with sufficiently stable fim3 expression to provide improved protection in mice against Fim3-only producing clinical B. pertussis isolates was developed. The fim3 expression in BPZE1f3 did not alter the protective efficacy against Fim2+ strains, nor against strains that produce neither Fim2 nor Fim3.

Formulations of lyophilized Bordetella bacteria which are stable for at least two years when stored at temperatures between -20° and 22.5° C., and which exhibit sufficient homogeneity (no bacterial clumping) bacterial viability and potency to be used as a live vaccine are made by harvesting Bordetella bacteria from a culture at an OD600 between 0.4 and 1.6; mixing the harvested Bordetella bacteria with a lyophilization buffer comprising 5-65% by weight a cryoprotectant sugar and having a temperature between 2-3 5° C., wherein the ratio of harvested Bordetella bacteria to lyophilization buffer is between 5:1 and 1:5 by volume; lyophilizing the mixture of the Bordetella bacteria and the lyophilization buffer; wherein the hold time between the harvesting and lyophilization steps is less than 48 hours; and collecting the lyophilized Bordetella bacteria.

As disclosed herein, fructose-asparagine (F-Asn) is a primary nutrient utilized during Salmonella-mediated gastroenteritis. Engineered bacteria are disclosed that can compete with Salmonella for F-Asn and other nutrients and withstand Salmonella-induced inflammation. These bacterium can be used as probiotics to treat and prevent Salmonella-mediated gastroenteritis.

The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberculosis complex, preferably a M. tuberculosis clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP− phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM− phenotype) (the MTB VAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberculosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.

The present disclosure provides immunogenic materials and methods useful for reducing the risk of fungal infections, particularly valley fever. The disclosure also provides assays for identifying compounds useful to treat valley fever, as well as methods for ameliorating the symptoms of valley fever.

Disclosed herein are unique adjuvant compositions comprising an attenuated derivative of a self-destructing bacterial pathogen that undergoes lysis in vivo. In exemplary embodiments, the bacterial pathogen is a Salmonella spp. Also disclosed are methods for enhancing an immune response using the adjuvants disclosed herein.